
PE-backed NutraQ sold to trade in NOK 3.1bn deal
NutraQ, backed by private equity firm Impilo and Sana Pharma Holding, has been sold to listed company Orkla for NOK 3.1bn (€303.5m).
The exit comes three years after Impilo, a Nordic investment company focused on investments in the healthcare sector, acquired a 51% stake in the company in December 2017.
Based on the company's 2020 EBITDA of NOK 188m, the deal achieved an EBITDA multiple of 16.5x.
The acquisition will help Orkla – a supplier of branded consumer goods to grocery stores and bakers – to "bring new competence, more sales channels and a larger international scope of growth", according to the company.
The deal is subject to regulatory approval.
Company
Founded in 2002 and based in Oslo, NutraQ is a supplier of subscription-based health and beauty products in the Nordic region.
It owns health and beauty brands VitaePro and Oslo Skin Lab, men's health brands Maxulin and Provexin, and vitamin supplement brand Vesterålens Naturprodukter. The company has 150 employees and reported a turnover of NOK 862m in 2020 and EBITDA of NOK 188m.
People
Orkla – Jaan Ivar Semlitsch (CEO).
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater